Multidrug-Resistant Tuberculosis*

A Menace That Threatens To Destabilize Tuberculosis

Control
1. Surendra K. Sharma, MD, PhD, FCCP and
2. Alladi Mohan, MD

+ Author Affiliations

1. From the Division of Pulmonary and Critical Care Medicine (Dr. Sharma), Department of
*

Medicine, All India Institute of Medical Sciences, New Delhi, India; and the Division of
Pulmonary and Critical Care Medicine (Dr. Mohan), Department of Medicine, Sri
Venkateswara Institute of Medical Sciences, Tirupati, India.
1. Correspondence to: Surendra K. Sharma, MD, PhD, FCCP, Chief, Division of Pulmonary
and Critical Care Medicine, Professor and Chairman, Department of Medicine, All India
Institute of Medical Sciences, New Delhi 110 029, India; e-mail: sksharma@aiims.ac.in

 
Next Section
Abstract
Multidrug-resistant tuberculosis (MDR-TB), caused by Mycobacterium tuberculosis that is
resistant to both isoniazid and rifampicin with or without resistance to other drugs, is a
phenomenon that is threatening to destabilize global tuberculosis (TB) control. MDR-TB is a
worldwide problem, being present virtually in all countries that were surveyed. According to
current World Health Organization and the International Union Against Tuberculosis and Lung
Disease estimates, the median prevalence of MDR-TB has been 1.1% in newly diagnosed
patients. The proportion, however, is considerably higher (median prevalence, 7%) in patients
who have previously received anti-TB treatment. While host genetic factors may contribute to
the development of MDR-TB, incomplete and inadequate treatment is the most important
factor leading to its development, suggesting that it is often a man made tragedy. Efficiently
run TB control programs based on a policy of directly observed treatment, short course (DOTS),
are essential for preventing the emergence of MDR-TB. The management of MDR-TB is a
challenge that should be undertaken by experienced clinicians at centers equipped with
reliable laboratory services for mycobacterial cultures and in vitro sensitivity testing as it the
requires prolonged use of costly second-line drugs with a significant potential for toxicity. The
judicious use of drugs; supervised standardized treatment; focused clinical, radiologic, and
bacteriologic follow-up; and surgery at the appropriate juncture are key factors in the
successful management of these patients. With newer effective anti-TB drugs still a distant
dream, innovative approaches such as DOTS-Plus are showing promise for the management of
patients with MDR-TB under program conditions and appear to be a hope for future.

 diagnosis

 epidemiology
  multidrug-resistant tuberculosis

 predictors for development

 prognostic factors

 treatment

 tuberculosis

Tuberculosis (TB) is a medical, social, and economic disaster of immense magnitude that is
occurring the world over.1 Strains of Mycobacterium tuberculosis that are resistant to both
isoniazid and rifampicin with or without resistance to other drugs have been termed
multidrug-resistant strains. Isoniazid and rifampicin are keystone drugs in the management of
TB. While resistance to either isoniazid or rifampicin may be managed with other first-line
drugs, multidrug-resistant TB (MDR-TB) demands treatment with second-line drugs that have
limited sterilizing capacity, and are less effective and more toxic. MDR-TB is one of the most
worrisome elements of the pandemic of antibiotic resistance. 23

Resistance to anti-TB drugs is usually described in terms of “resistance among new cases” and
“resistance among previously treated patients.” 4 The term susceptible strains refers to those
strains that have not been exposed to the first-line anti-TB drugs and respond to these drugs
in a uniform manner. The term resistant strains refers to those strains that differ from the
sensitive strains in their capacity to grow in the presence of a higher concentration of a drug. 3

Previous SectionNext Section

Epidemiology
Though published studies from the developing world have suggested that drug resistance was
a potential problem,3 it was the emergence of MDR-TB in the United States in the 1990s that
attracted the attention.56 The global extent of the problem of drug-resistant TB is evident from
the three rounds of surveys coordinated by World Health Organization (WHO) and the
International Union Against Tuberculosis and Lung Disease between 1996 and 2002. The third
round of surveys7 included new data from 77 settings or countries that were collected between
1999 and 2002. Among new cases (Fig 1 , top, A), the prevalence of MDR-TB (median,1.1%)
ranged from 0% in eight countries to 14.2% in Kazakhstan (51 of 359 patients) and Israel (36 of
253 patients). Among previously treated cases (Fig 1, bottom, B), the median prevalence of
MDR-TB was 7.0%. In the latest survey, 7 as in the two previous surveys, MDR-TB was found in
all regions of the world. The prevalence of MDR-TB was exceptionally high in almost all
countries from the former Soviet Union that were surveyed, including Estonia, Kazakhstan,
Latvia, Lithuania, the Russian Federation, and Uzbekistan. High prevalences of MDR-TB were
also found among new cases in China (Henan and Liaoning provinces), Ecuador, and Israel.
Central Europe and Africa, in contrast, reported the lowest median levels of drug resistance.
Recent estimates8 from 184 countries suggest that an estimated 458,000 new cases of MDR-TB
occurred worldwide in 2003, with 276,000 of those cases (60%) reported from high-burden
countries China and India constituting 3.2% of all new TB cases. However, it should be
remembered that increases in the prevalence of resistance can be caused by poor or worsening
TB control, the immigration of patients from areas of higher resistance, outbreaks of drug-
resistant disease, and variations in surveillance methodologies. 3

View larger version:

 In this page
 In a new window

 Download as PowerPoint Slide

Figure 1.

Top, A: prevalence of MDR-TB in new cases from 1994 to 2002. Bottom, B: prevalence of MDR-
TB in previously treated cases from 1994 to 2002. Reproduced with permission from World
Health Organization, International Union Against Tuberculosis and Lung Disease. 7

Previous SectionNext Section

Molecular Basis of Drug Resistance
Spontaneous chromosomally borne mutations occurring in M tuberculosis at a predictable rate
are thought to confer resistance to anti-TB drugs. 39 A characteristic feature of these mutations
is that they are unlinked. A TB cavity usually contains 10 7 to 109 bacilli. If mutations causing
resistance to isoniazid occur in about 1 in 10 6 replications of bacteria, and the mutations
causing resistance to rifampicin occur in about 1 in 10 8 replications, the probability of
spontaneous mutations causing resistance to both isoniazid and rifampicin would be 10 6 × 108
= 1 in 1014 replications.3 Given that this number of bacilli cannot be found even in patients with
extensive cavitary pulmonary TB, the chance of the development of spontaneous dual
resistance to rifampicin and isoniazid is practically remote.39

Table 1 lists the perturbations in the individual drug target genes that are responsible for the
genesis of anti-TB drug resistance. 39 Rifampicin resistance has been shown to be caused by an
alteration of the β-subunit of RNA polymerase, which is encoded by the rpoβ gene. More than
95% of rifampicin-resistant strains are associated with mutations within an 81-base pair region
of the rpoβ gene, which is termed the rifampicin resistance determinant region .10 On the
contrary, resistance to isoniazid is more complicated, as mutations in several genes 1011 can lead
to drug resistance (Table 1).

View this table:

 In this window
 In a new window

Table 1.

Antituberculosis Drugs and the Genes Involved in Their Resistance

While certain mutations are widely present, pointing to the magnitude of the polymorphisms at
these loci, others are not common, suggesting diversity in the multidrug-resistant M
tuberculosis strains that are prevalent in the given region. Furthermore, rifampicin resistance
has been considered to be a surrogate marker for checking multidrug resistance in clinical
isolates of M tuberculosis since rifampicin resistance is often accompanied by resistance to
isoniazid.12

Previous SectionNext Section

Potential Causes of Drug Resistance
Following factors have been implicated in the causation of MDR-TB.313

Factors Related to Previous Treatment

In most of the published studies, a history of TB and anti-TB treatment have been implicated in
the causation of MDR-TB.314151617

Incomplete and Inadequate Treatment:

A review of the published literature strongly suggests that the most powerful predictor of the
presence of MDR-TB is a history of treatment of TB (Table 2 ). Errors in TB management such
as the use of single drug to treat TB, the addition of a single drug to a failing regimen, the
failure to identify preexisting resistance, the initiation of an inadequate primary regimen, the
failure to identify and address nonadherence to treatment, inappropriate isoniazid preventive
therapy, and variations in the bioavailability of anti-TB drugs predispose the patient to the
development of MDR-TB.18

View this table:

 In this window
 In a new window

Table 2.

Causes of Inadequate Treatment*

Inadequate Treatment Adherence:
Nonadherence to prescribed treatment is often underestimated by the physician and is difficult
to predict. In the West, demographic factors such as age, sex, marital status, education level,
and socioeconomic status have not been found to correlate with the degree of treatment
adherence. On the other hand, certain factors such as psychiatric illness, alcoholism, drug
addiction, and homelessness do predict nonadherence to treatment. 3 The directly observed
treatment, short-course (DOTS) strategy, which has been endorsed by the WHO as the only
effective way to control TB, has to some extent addressed these problems. 418 In India,
innovative measures such as public-private mix and the use of Anganwadi workers have been
tried out under program conditions to improve treatment adherence in patients with TB in
general, and these measures would help patients with MDR-TB also. The reader can find more
details on this topic at the Web site http://www.tbcindia.org.

Logistic Issues

Good, reliable laboratory support is seldom available in developing nations. When facilities for
growing cultures and sensitivity testing are not available, therapeutic decisions are most often
made by algorithms or inferences from previous treatment. 19 While DOTS has been shown to
reduce the transmission and incidence of both drug-susceptible and drug-resistant TB even in
settings with moderate rates of MDR-TB, 20 it has been observed that the “programmatic
approach” to the management of patients who do not respond to treatment may fail in certain
settings.2122 First-line therapy may not be sufficient in settings with a high degree of resistance
to anti-TB drugs.21 Although the DOTS strategy is the basis of good TB control, the strategy
should be modified in some settings to identify drug-resistant cases sooner and to make use
of second-line drugs in appropriate treatment regimens.523

Virulence of the Organism

Substantial progress has been made in the understanding of the molecular epidemiology of
tubercle bacilli with the availability of genome sequence data in the public domain (available at
http:www.cdfd.org.in/amplibase; http://www.cdc.gov/ncidod/EID/vol7no3/sola_data.htm; and
https://hypocrates.rivm.nl/bnwww/IS6110-RFLP-bands.htm). Phylogenomic analysis suggests
that the “ancient strains” of M tuberculosis may have undergone adaptive evolution as a result
of selection at many loci.23

Extrapolating data on the virulence and survival capability of isoniazid-resistant strains to

multidrug-resistant strains of M tuberculosis, it has been assumed that multidrug-resistant
isolates have lower virulence and survival capability. 3 It has been observed that emergence of
multidrug resistance may result in the organism becoming unusually fit to survive. This is
exemplified by a genotype, which was first described in 1995, known as the W-Beijing family.
Published reports2425 have suggested that W-Beijing genotype is highly prevalent in some
regions of Asia and Eastern Europe such as Estonia, Azerbaijan, and Russia. The strains
belonging to the W-Beijing family have been shown to exhibit a constant spoligotype and high
degrees of similarity among IS6110 restriction fragment length polymorphism (RFLP),
polymorphic GC-rich sequence RFLP, and variable numbers of tandem repeats profiles. W-
Beijing genotype is well-known for its rapidity of spread and tenacity, and notably for its
strong association with multidrug resistance. 2425 Given that the Beijing strain has already made
its appearance in India where 20% of the TB patients in the world are located, the consequences
can be disastrous. 26 However, caution must be exercised while interpreting these data as these
observations need to be validated in multiple settings before definitely linking the clone to the
given host population.23

Multidrug Transporters

Multidrug transporters mediate both intrinsic and acquired resistance to various drugs. 27 P-
glycoprotein is a human analog of these multidrug transporters and is expressed on immune
effector cells. The infection of experimental cell lines by M tuberculosis results in the increased
expression of P-glycoprotein and the decreased accumulation of isoniazid inside the cells.
Apart from the up-regulation of host cell P-glycoprotein, M tuberculosisper se expresses at
least three multidrug transporter proteins such as Tap, Lfr A, and Mmr. 327 Evidence is available
demonstrating a clear association between multidrug resistance and transcription levels of a
Tap-like pump (Rv1258c) and the overexpression of an efflux protein. 28 The potential
contribution of these multidrug transporter proteins in the causation of MDR-TB merits further
evaluation. They also appear to be novel targets for drug therapy in the future.

Host Genetic Factors

Though there is some evidence to postulate host genetic predisposition as the basis of the
development of MDR-TB, it has not been conclusive. 2930 Associations among HLA-DRB1*1,
DRB1*14,29 and HLA-DRB1*0803 haplotypes,30 and the susceptibility to MDR-TB suggests that
these loci or the alleles linked with them play a permissive role in conferring increasing
susceptibility to the development of MDR-TB. These issues merit further study.

HIV Infection

A review of the published literature 23 suggests that, in the early 1990s, several institutional
outbreaks of MDR-TB among HIV-infected patients drew attention to the problem. Current
evidence suggests that HIV infection per se does not appear to be a predisposing factor for the
development of MDR-TB. Some studies3132 have found that MDR-TB is not more common
among people infected with HIV. However, increased susceptibility to TB, increased opportunity
to acquire TB due to overcrowding, exposure to patients with MDR-TB due to increased
hospital visits, and malabsorption of anti-TB drugs resulting in suboptimal therapeutic blood
levels despite strict adherence to the treatment regimen potentially increase the chances of
MDR-TB occurring in persons with HIV/AIDS, if not adequately addressed. 3

Previous SectionNext Section

Diagnosis of MDR-TB
Conventional Methods

Traditionally, Lowenstein-Jensen culture has been used for drug sensitivity testing using (1) the
absolute concentration method, (2) the resistance ratio method, and (3) the proportion
method.3 With the conventional methods, a duration of 6 to 8 weeks is required before
sensitivity results are known.

Newer Methods

Several newer methods have been developed to document anti-TB drug resistance faster. Most
of these methods are expensive and are not available in the field setting. Radiometric methods
(eg, BACTEC-460; Becton-Dickinson; Franklin Lakes, NJ) have been developed for rapid drug-
susceptibility testing of M tuberculosis by which results are available within 10 days. 333 The
mycobacteria growth indicator tube system (Becton-Dickinson) is a rapid, nonradioactive
method for the detection and susceptibility testing of M tuberculosis.333 Ligase chain reaction
facilitates the detection of a mismatch of even one nucleotide. 333 Luciferase reporter assay is a
reporter gene assay system for the rapid determination of drug resistance that can identify
most strains within 48 h.333 As rifampicin resistance is considered to be a surrogate marker for
MDR-TB, techniques such as a rapid bacteriophage-based test (FASTPlaqueTB-RIF; Biotec
Laboratories; Ipswich, UK) that is used to identify rifampicin susceptibility in clinical strains of
M tuberculosis after growth in a semi-automated liquid culture system (BACTEC-460; Becton-
Dickinson) have also shown potential to diagnose MDR-TB.1434

Polymerase chain reaction (PCR)-based sequencing has often been employed to understand the
genetic mechanisms of drug resistance in patients with M tuberculosis.3333435 RFLP patterns have
been used to categorize and compare isolates of M tuberculosis.35 As the DNA fingerprints of M
tuberculosis have been observed not to change during the development of drug resistance,
RFLP analysis has also been used to track the spread of drug-resistant strains. 35 Molecular
markers for epidemiologic and evolutionary studies such as mycobacterial interspersed repeat
units-variable number tandem repeats, fluorescent amplified fragment length polymorphism
have been used to study the molecular epidemiology of M tuberculosis.143637 Spoligotyping,
which is based on the variability in the direct-repeat locus of M tuberculosis, has been useful in
detecting new outbreaks as well as in tracking TB epidemics.23

Molecular assays,143839 such as heteroduplex and mismatch analyses, DNA sequencing, real-time
PCR, molecular beacons, and line probe assays have all been used to screen for mutations that
are responsible for the development of anti-TB drug resistance. Multiplex PCR, followed by
hybridization on an oligonucleotide microarray,40 or low-density DNA oligonucleotide array
(macroarray)10 have also been used to detect the DNA of M tuberculosis complex and to identify
mutations associated with isoniazid and rifampicin resistance.

Previous SectionNext Section

Management
The treatment of MDR-TB is a challenge which should be undertaken by experienced clinicians
at centers equipped with reliable laboratory service for mycobacterial culture and in vitro
sensitivity testing.341 In the early reports of outbreaks of MDR-TB in HIV-coinfected patients in
hospitals and prisons, the mortality rate was very high (range, 72 to 89%). 3 However,
subsequent studies3 have documented decreased mortality and improvement in clinical
outcome for both HIV-seropositive and HIV-seronegative patients with MDR-TB.
Principles of Management

When MDR-TB is suspected on the basis of history or epidemiologic information, the patient’s
sputum must be subjected to culture and anti-TB drug-sensitivity testing. These patients may
be started on WHO category II treatment42 (under program conditions) or the regimens
employing various drugs (Table 4 ), such as those suggested by the American Thoracic Society,
the Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of
America43 pending sputum culture report. Further therapy is guided by the culture and
sensitivity report. These guidelines clearly mention that a single drug should never be added to
a failing regimen. Furthermore, when initiating treatment, at least three previously unused
drugs must be employed to which there is in vitro susceptibility.1943 These guidelines43 suggest
that among the fluoroquinolone levofloxacin is best suited for the treatment of MDR-TB, given
its good safety profile with long-term use. The results of a study 44 of community-based
outpatient treatment of MDR-TB reported from Peru suggest that community-based outpatient
treatment of patients with MDR-TB is possible with high cure rates even in resource-poor
settings.

View this table:

 In this window
 In a new window

Table 3.

Drugs Useful in the Treatment of MDR-TB*

View this table:

 In this window
 In a new window

Table 4.

Comparison of the Principles Underlying DOTS and the DOTS-Plus Strategies *

Need for Standard Definitions

No randomized controlled trials exist addressing the issue of the optimal management strategy
for MDR-TB. As in the case with the DOTS strategy, the systematic study of the efficacy of
DOTS-Plus regimens requires the standardization of definitions for MDR-TB case registration
and treatment outcomes. Such definitions would permit the accumulation of evidence and
would facilitate cross-program comparisons. The reader is referred to the study by Laserson et
al45 for these definitions.

DOTS-Plus Strategy

DOTS is a key ingredient in the TB control strategy. In populations in which MDR-TB is

endemic, the outcome of the standard short-course regimen remains uncertain. 13 As a
consequence, there have been calls for well-functioning DOTS programs to provide additional
services in areas with high rates of MDR-TB. In order to promote the programmatic treatment
of MDR-TB in low-income and middle-income countries that have adopted the DOTS strategy,
the WHO and its international partners have been evolving the “DOTS-Plus for MDR-TB
programs” (Table 4) since 1998.1341 The WHO has also established a unique partnership known
as the Green Light Committee to lower the prices of and to increase control over second-line
anti-TB drugs, and to date 35 DOTS-Plus projects are underway across the globe. 46474849 The
DOTS-Plus strategy of identifying and treating patients with MDR-TB appears to have the
potential to be effectively implemented on a nationwide scale even in a setting with limited
resources.17

The results from the retrospective study 50 designed to assess treatment outcomes for the first
full cohort of MDR-TB patients (n = 204), who were treated under the Latvian DOTS-Plus
strategy following WHO guidelines, have been encouraging; 66% patients were cured or
completed therapy, 7% died, 13% defaulted, and 14% did not respond to treatment. Data on
adverse drug reactions (ADRs) collected from five DOTS-Plus sites in Estonia, Latvia, Peru
(Lima), the Philippines (Manila), and the Russian Federation (Tomsk Oblast) 51 showed that,
among 818 patients enrolled for MDR-TB treatment, only 2% of patients stopped treatment and
30% required removal of the suspected drugs from the regimen and use of alternative drugs
due to ADRs. These findings indicate that ADRs are manageable in the treatment of MDR-TB
even in resource-limited settings provided that standardized management strategies are
followed.

Monitoring Response to Treatment

Patients receiving treatment for MDR-TB should be closely followed up. Clinical, radiologic,
laboratory, and microbiological parameters should be frequently reviewed to assess the
response to treatment. Additionally, considerable attention must be focused on monitoring the
ADRs.3

Prognostic Markers

Table 5 summarizes markers of poor prognosis in patients with MDR-TB. Recognition of these
factors may help clinicians to monitor the patients more closely and to correct remediable
factors such as malnutrition.3445052535455

View this table:

 In this window
 In a new window

Table 5.

Markers of Poor Prognosis in Patients With MDR-TB

Newer Anti-TB Drugs

Patients are 4 to 10 times more likely to not respond to the currently available drugs used to
treat MDR-TB (Table 3) than to the standard therapy for drug-susceptible TB. 3 After the
introduction of rifampicin, no worthwhile anti-TB drug with new mechanisms of action has
been developed in > 30 years. Some of the older drugs that are being tested and the newer
drugs with potential as anti-TB agents that are at various stages of development are listed in
Table 6 .

View this table:

 In this window
 In a new window

Table 6.

Some of the Older Drugs and Newer Drugs With Potential as Anti-TB Agents at Various Stages
of Development*

A series of compounds containing a nitroimidazopyran nucleus that have shown anti-TB

activity have been described.56 After activation by a mechanism that is dependent on M
tuberculosis F420 cofactor, nitroimidazopyrans inhibited the synthesis of protein and cell wall
lipid, and exhibited bactericidal activity against both replicating and static M tuberculosis.
Compound PA-824 showed potent bactericidal activity against MDR-TB and promising oral
activity in animal infection models. 5758 Further, compounds belonging to the class pyrroles,
such as LL3858 and LL3522, are also evoking interest. 56 Recently, Andries et al59 reported a new
class of inhibitors (diarylquinolines) that blocks the function of an essential membrane-bound
enzyme that makes adenosine triphosphate. Of the 20 interesting drug candidates, R207910
showed the best activity profile, is bactericidal, and is exceptionally specific against
mycobacteria, with little or no activity against the other microorganisms tested. Furthermore,
R207910 is active against both the drug-sensitive and drug-resistant forms of M tuberculosis.
There have also been reports60 of novel ring-substituted-1Himidazole-4-carboxylic acid ethyl
esters as a new class of anti-TB agents. Whether the initial enthusiasm with these newer
compounds will eventually become established as practically useful newer first-line anti-TB
drugs remains to be seen.

Surgery

Surgery is currently recommended for MDR-TB patients whose prognosis with medical
treatment is poor and can be performed with a low mortality rate (< 3%). 3 The operative risks
are acceptable, and the long-term survival is much improved over that with continued medical
treatment alone. However, for this to be achieved, the chemotherapeutic regimen needs to
continue for prolonged periods after surgery, probably for well > 1 year, otherwise
recrudescence of the disease with poor survival is a real possibility. 3

Nutritional Enhancement

TB is a wasting disease. The degree of cachexia is most profound when MDR-TB occurs in
patients with HIV infection/AIDS. Furthermore, several second-line drugs used to treat MDR-
TB, such as para-aminosalicylic acid and fluoroquinolones, cause significant anorexia, nausea,
vomiting, and diarrhea, which interfere with food intake, further compromising the cachectic
state. Therefore, nutritional assessment and regular monitoring of the nutritional state by a
dietician are essential for the successful management of MDR-TB patients and should be an
essential part of such programs.3

Immunotherapy

Since the early efforts by Robert Koch, several attempts have been made to modify the immune
system of patients with TB to facilitate a cure. Some of the methods currently being tried are
discussed below.

Mycobacterium vaccae Vaccination

Transiently favorable results were observed61 when immunoenhancement using M vaccae

vaccination was used to treat drug-resistant TB patients who did not respond to chemotherapy.
However, definite evidence confirming these observations is expected from randomized
controlled trials.62

Mycobacterium w

Results from controlled studies6364 suggest that adjuvant therapy with Mycobacterium w
vaccination along with anti-TB drugs is well-tolerated and facilitates early sputum conversion.
A large-scale multicenter trial that is already underway is expected to provide definitive
evidence regarding this treatment modality in category II TB patients (see http://
www.clinicaltrials.gov/ct/show/NCT00265226?order = 1).

Cytokine Therapy

Aerosolized IFN-γ, granulocyte-macrophage colony-stimulating factor-aerosolized IFN-α, and

low-dose recombinant human interleukin-2 may have all been used as adjunctive treatment for
patients with MDR-TB.3 Evidence establishing their efficacy, optimal dosage, and schedule,
however, needs to be generated in further studies.

Other Agents

Other agents used in the treatment of MDR-TB are listed in Table 7 .3 Although there have been
anecdotal reports of their usefulness, further studies are required to clarify their role.

View this table:

 In this window
 In a new window

Table 7.

Other Agents Used in the Treatment of MDR-TB*

Prevention of Transmission of MDR-TB

As TB poses a significant risk to health-care workers, doctors, and other patients,
recommendations such as those issued by the WHO 65 and the CDC in Atlanta, GA,66 regarding
the prevention of the transmission of TB in hospitals, workplaces, and institutional settings
should be implemented wherever it is feasible.

Treatment of Latent MDR-TB Infection

Newer IFN-γ-based assays show potential for the diagnosis of latent MDR-TB infection. For
contacts thought to be infected with M tuberculosis that is resistant to both isoniazid and
rifampicin, no satisfactory chemoprophylaxis is available. 67 There is no consensus regarding
the choice of the drugs and the duration of treatment. The CDC has put forth guidelines 66 for
the management of persons exposed to MDR-TB. The two suggested regimens for MDR-TB
preventive therapy are as follows 68: (1) pyrazinamide (25 to 30 mg/kg daily) plus ethambutol
(15 to 25 mg/kg daily); or (2) pyrazinamide (25 to 30 mg/kg daily) plus a quinolone with anti-
TB activity (eg, levofloxacin or ofloxacin). The recommended duration of therapy is 12 months
for those patients with underlying immunosuppression and at least 6 months for all other
patients. All patients should be closely observed for at least 2 years, and a low threshold for
referral to a center with experience in managing MDR-TB should be maintained. Initial results
indicate that the pyrazinamide and levofloxacin regimen was found to be poorly tolerated as
severe ADRs developed in several patients. These issues merit further study in randomized
controlled studies.

Future Directions

The efficacy of strategies such as DOTS-Plus in the management of MDR-TB patients under
program conditions should be tested in well-designed operational field clinical trials strictly
following standardized definitions and nomenclature. Ethnic variations in the pharmacokinetics
of anti-TB drugs and the utility of therapeutic drug monitoring in the management of patients
with MDR-TB need further study. The field testing of newer anti-TB drugs that is on the
horizon and generating evidence regarding their efficacy deserves special mention as there is
renewed hope of shortening the duration of treatment.

Previous SectionNext Section

Acknowledgments
We sincerely thank Dr. L.S. Chauhan, Deputy Director General (TB), Central TB Division,
Directorate General of Health Services, Ministry of Health and Family Welfare, Government of
India; and Dr. Fraser Wares, STP (TB), Office of the WHO Representative to India, New Delhi, for
critically reading the manuscript and providing valuable suggestions.

Previous SectionNext Section

Footnotes
 Abbreviations: ADR = adverse drug reaction; CDC = Centers for Disease Control and
Prevention; DOTS = directly observed treatment, short-course; MDR-TB = multidrug-
 resistant tuberculosis; PCR = polymerase chain reaction; RFLP = restriction fragment
length polymorphism; TB = tuberculosis; WHO = World Health Organization

 Drs. Sharma and Mohan have no financial interests in the subject of this article and no
conflicts of interest to report.


o Received January 31, 2006.

o Accepted March 31, 2006.